Lymphocytic tumor necrosis factor receptor superfamily co-stimulatory molecules in the pathogenesis of atherosclerosis

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 518-524

  Smeets, Esther ^a   Meiler, Svenja ^a   Lutgens, Esther ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

adaptive immune system; atherosclerosis; co stimulatory molecules; lymphocytes; tumor necrosis factor receptor superfamily

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; OX40 LIGAND; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CYTOKINE RELEASE; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LYMPHOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84888302854     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000025     Document Type: Review

References (71)

1. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010; 134:33-46.
2. Lichtman AH, Binder CJ, Tsimikas S, et al. Adaptive immunity in atherogenesis: New insights and therapeutic approaches. J Clin Invest 2013; 123:27-36
3. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:2045-2051
4. Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102:2919-2922.
5. Elhage R, Gourdy P, Brouchet L, et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am J Pathol 2004; 165:2013-2018.
6. Klingenberg R, Lebens M, Hermansson A, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:946-952.
7. Weih F, Grabner R, Hu D, et al. Control of dichotomic innate and adaptive immune responses by artery tertiary lymphoid organs in atherosclerosis. Front Physiol 2012; 3:226.
8. Kyaw T, Tay C, Krishnamurthi S, et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011; 109:830-840.
9. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119:1335-1349.
10. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207:1579-1587.
11. Kyaw T, Tay C, Khan A, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010; 185:4410-4419.
12. Lappalainen J, Lindstedt KA, Oksjoki R, et al. OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells. Atherosclerosis 2011; 214:357-363.
13. Montecucco F, Vuilleumier N, Pagano S, et al. Anti-Apolipoprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32:412-421.
14. Perry HM, Bender TP, McNamara CA. B cell subsets in atherosclerosis. Front Immunol 2012; 3:373.
15. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591-619.
16. Lievens D, Eijgelaar WJ, Biessen EA, et al. The multifunctionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102:206-214.
17. Antunes RF, Kaski JC, Dumitriu IE. The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis. J Biomed Biotechnol 2012; 2012:464532
18. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5:1313-1316.
19. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394:200-2003.
20. Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000; 97:7458-7463.
21. Saoulli K, Lee SY, Cannons JL, et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998; 187:1849-1862.
22. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997; 94:1931-1936.
23. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membranebound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100:614-620.
24. Wang C, Yan J, Yang P, et al. The relationship between CD40 gene polymorphism and unstable coronary atherosclerotic plaques. Clin Cardiol 2010; 33:E55-E60.
25. Olofsson PS, Soderstrom LA, Wagsater D, et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008; 117:1292-1301.
26. Dongming L, Zuxun L, Liangjie X, et al. Enhanced levels of soluble and membrane-bound CD137 levels in patients with acute coronary syndromes. Clin Chim Acta 2010; 411:406-410.
27. Yan J, Wang C, Chen R, et al. Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome. Clinics (Sao Paulo) 2013; 68:193-198.
28. van Olffen RW, de Bruin AM, Vos M, et al. CD70-driven chronic immune activation is protective against atherosclerosis. J Innate Immun 2010; 2:344-352.
29. de Boer OJ, Hirsch F, van der Wal AC, et al. Costimulatory molecules in human atherosclerotic plaques: An indication of antigen specific T lymphocyte activation. Atherosclerosis 1997; 133:227-234.
30. Wang X, Ria M, Kelmenson PM, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37:365-372.
31. Nakano M, Fukumoto Y, Satoh K, et al. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc Res 2010; 88:539-546.
32. van Wanrooij EJ, van Puijvelde GH, de Vos P, et al. Interruption of the Tnfrsf4/ Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:204-210.
33. Yan J, Su H, Xu L, et al. OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice. PLoS One 2013; 8:E60854.
34. Kim WJ, Bae EM, Kang YJ, et al. Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology 2006; 119:421-429.
35. de Boer OJ, van der Meer JJ, Teeling P, et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007; 2:E779.
36. Foks AC, Bot I, Frodermann V, et al. Interference of the CD30-CD30L pathway reduces atherosclerosis development. Arterioscler Thromb Vasc Biol 2012; 32:2862-2868
37. Mahmoudi MJ, Hedayat M, Rezaei N, et al. In vitro soluble CD30 levels in patients with chronic stable coronary artery disease. Iran J Allergy Asthma Immunol 2011; 10:237-242.
38. Watt V, Chamberlain J, Steiner T, et al. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011; 215:348-354.
39. Di Bartolo BA, Chan J, Bennett MR, et al. TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe -/- mice. Diabetologia 2011; 54:3157-3167.
40. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005; 45:1018-1024.
41. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008; 75:1441-1450.
42. Ha H, Han D, Choi Y. TRAF-mediated TNFR-family signaling. Curr Protoc Immunol 2009; Chapter 11:Unit11 9D.
43. Zirlik A, Bavendiek U, Libby P, et al. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 1101-1107.
44. Leo E, Welsh K, Matsuzawa S, et al. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation. J Biol Chem 1999; 274:22414-22422.
45. Polykratis A, van Loo G, Xanthoulea S, et al. Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis. Circulation 2012; 126:1739-1751
46. Missiou A, Kostlin N, Varo N, et al. Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation 2010; 121:2033-2044.
47. Missiou A, Rudolf P, Stachon P, et al. TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res 2010; 107:757-766.
48. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A 2005; 102:2874-2879.
49. Urbich C, Mallat Z, Tedgui A, et al. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 2001; 108:1451-1458.
50. Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation 2003; 108:1619-1625.
51. Pamukcu B, Lip GY, Snezhitskiy V, et al. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43:331-340.
52. Mackey MF, Wang Z, Eichelberg K, et al. Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion. Eur J Immunol 2003; 33:779-789.
53. Song Z, Jin R, Yu S, et al. CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One 2011; 6:E23239.
54. Bavendiek U, Zirlik A, LaClair S, et al. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2005; 25:1244-1249.
55. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207:391-404.
56. Zirlik A, Maier C, Gerdes N, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115: 1571-1580.
57. Balla J, Magyar MT, Bereczki D, et al. Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease. Dis Markers 2006; 22:133-140.
58. Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002; 106:896-899.
59. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011; 89:195-203.
60. Arens R, Tesselaar K, Baars PA, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15:801-812.
61. Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004; 173:3901-3908.
62. Munitic I, Kuka M, Allam A, et al. CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus. J Immunol 2013; 190:1169-1179.
63. Coquet JM, Middendorp S, van der Horst G, et al. The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity 2013; 38:53-65
64. Klingenberg R, Gerdes N, Badeau RM, et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013; 123:1323-1334
65. Coquet JM, Ribot JC, Babala N, et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med 2013; 210:715-728.
66. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007; 110:2501-2510.
67. Song J, So T, Croft M. Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 2008;180:7240-7248.
68. So T, Choi H, Croft M. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J Immunol 2011; 186:3547-3555.
69. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptorassociated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18:558-565.
70. Sabbagh L, Pulle G, Liu Y, et al. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol 2008; 180:8093-8101.
71. Jeon HJ, Choi JH, Jung IH, et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010; 121:1124-1133.